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Background: Graves’ hyperthyroidism is an autoimmune disease causing hyperfunction of the thyroid gland. The
concentration of selenium is high in the thyroid gland and two important groups of enzymes within the thyroid
are selenoproteins, that is, they depend on selenium. Selenium may have beneficial effects on autoimmune
hypothyroidism and on Graves' orbitopathy, but the effects of selenium on Graves' hyperthyroidism is unknown.
We hypothesize that adjuvant selenium may be beneficial in the treatment of Graves' hyperthyroidism. The
objective is to investigate if selenium supplementation plus standard treatment with anti-thyroid drugs versus
standard treatment with anti-thyroid drugs will lead to a decrease in anti-thyroid drug treatment failure (that is,
failure to remain euthyroid, without further treatment, one year after cessation of anti-thyroid drug treatment),
faster and longer lasting remission (that is, anti-thyroid drug treatment success), and improved quality of life in
patients with Graves’ hyperthyroidism.
Methods and design: The trial is an investigator-initiated, randomised, blinded, multicentre clinical trial. Inclusion
criteria are: age 18 years or older; diagnosis of active Graves' hyperthyroidism within the last two months; and
informed consent. Exclusion criteria are major co-morbidity; previous radioactive iodine treatment; ongoing
anti-thyroid drug treatment for more than two months; treatment with immunomodulatory drugs; known allergy
towards the components in the selenium and placebo pills; pregnancy or breast-feeding; and intake of selenium
supplementation above 70 μg per day. We plan to include 492 participants, randomised (1:1) to two tablets of 100 μg
selenium once daily for the 24 to 30 months intervention period versus two identical placebo tablets once daily.
The primary outcome is the proportion of participants with anti-thyroid drug treatment failure (see above) at the end
of the intervention period (24 to 30 months). Secondary outcomes are: thyroid-specific quality of life during the first
year after randomisation; level of thyroid stimulating hormone-receptor antibodies at 18 months after randomisation
and at the end of the intervention period (24 to 30 months); hyperthyroid symptoms during the first year after
randomisation; eye symptoms during the first year after randomisation, and at the end of the intervention period
(24 to 30 months); adverse reactions during the intervention period; and serious adverse events during the
intervention period.
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Discussion: It was of great importance to the initiators of this trial, that the results would be directly applicable to
daily clinical practice. Therefore, it was designed as a pragmatic trial: the patients follow their usual treatment at
their usual hospitals. In order to still collect high quality data on the clinical course and quality of life, an elaborate
trial management system was designed to keep track of patient input, need for trial personnel input and action,
and to collect data from medical chart systems. Meticulous follow-up on missing responses to the QoL measurements
has been incorporated into the system, to minimise missing quality of life data. Monitoring of adverse reactions and
events is achieved by thorough instruction of the participants, surveillance of patient-reported outcomes, and
integration with national databases regarding hospitalizations. A very long intervention period was necessary, since
patients are not considered in remission until one year after stopping anti-thyroid drugs. Usually, patients are treated
for 12 to 18 months with anti-thyroid drugs, yielding a total intervention period of 24 to 30 months.
Trial registration: ClinicalTrials.gov: NCT01611896.
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Graves’ hyperthyroidism is an autoimmune disease caus-
ing hyperfunction of the thyroid gland by a mechanism,
where auto-antibodies bind to and stimulate the thyroid
stimulating hormone (TSH) receptor. It affects individ-
uals of all ages and is five to ten times more common in
women than in men, with an overall annual incidence in
Denmark of about 1,700 patients in 5.5 million people
[1]. Treatment of Graves’ hyperthyroidism comprise: 1)
anti-thyroid drugs (ATD) (for example, methimazole or
propylthiouracil); 2) thyroidectomy, that is, surgical re-
moval of the thyroid gland, and 3) radioactive iodine
treatment (I131), which permanently reduces thyroid func-
tion. In Europe, the primary treatment is usually ATD,
which leads to resolution of hyperthyroidism (that is,
euthyroidism) in 85% to 90% of patients within 6 weeks
[2]. This treatment is usually continued for a period of 12
to 18 months and then tapered off (ATD treatment with-
drawal). However, 30% to 60% of patients will experience
relapse of hyperthyroidism during the following years [2].
Patients with Graves' hyperthyroidism suffer from a wide
range of symptoms and have major impairments in most
areas of quality of life (QoL) [3].
Selenium is an essential trace element important for
human health. The main dietary sources of selenium in
Denmark are meat, poultry, dairy products, bread, cereals
and fish [4,5]. The recommended daily intake of selenium
is 40 μg for women and 50 μg for men. The estimated
actual daily intake in Denmark is considered sufficient,
but it cannot be ruled out that about 10% of the Danish
population could benefit from selenium supplementa-
tion [4]. The upper tolerable level of selenium intake is
set to 400 μg per day in the USA [6] and 300 μg per day
in the EU [7].
The thyroid gland has the highest selenium concen-
tration per unit weight among all tissues. Selenium is
incorporated into key enzymes involved in several meta-
bolic pathways. The main selenoprotein families are theglutathione peroxidases, the thioredoxin reductases and
the iodothyronine deiodinases [5]. It is hypothesized that
the glutathione peroxidases and the thioredoxin reduc-
tases participate in a complex defence system maintaining
normal thyroid function by protecting the gland from both
hydrogen peroxide, which is produced by the thyrocytes,
and reactive oxygen intermediates [8,9]. It has thus been
hypothesized, that selenium may have a beneficial role in
autoimmune thyroid diseases, by blunting the autoimmune
process.
We have not identified any published randomised tri-
als of selenium supplementation in patients with Graves’
hyperthyroidism. On ClinicalTrials.gov, one ongoing
randomised trial is registered on selenium supplementa-
tion in Graves’ thyrotoxicosis (NCT01247077). This trial
assesses neuropsychological well-being (not otherwise
specified), after nine months intake of 200 μg selenium,
and includes 44 participants. In a multicentre trial among
159 patients with mild Graves' orbitopathy, without hyper-
thyroidism, 200 μg selenium selenite improved disease-
specific QoL (P <0.001) and reduced eye disease severity
(P = 0.01) [10]. Another trial evaluated the effect of adding
a mixture of antioxidants, including 60 μg of selenium
(not otherwise specified) to standard ATD treatment in
29 patients with Graves' disease. During the 60-day fol-
low up period euthyroidism was reached more rapidly
in patients receiving antioxidants [11-13]. In contrast,
several randomised trials have evaluated the effect of
selenium on the other major autoimmune thyroid disease:
autoimmune hypothyroidism. In six [14-19] of seven [14-20]
placebo-controlled clinical trials, selenium treatment re-
duced thyroid peroxidase antibody (TPOAb) levels, indi-
cating a beneficial effect on the autoimmune activity.
We hypothesize that the addition of selenium supple-
mentation to the standard treatment with ATD in patients
with active Graves’ hyperthyroidism will lead to a decrease
in ATD treatment failure (that is, fewer patients with re-
lapse), faster remission, and improved quality of life.
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Objectives
The primary objective is to investigate the effect of selen-
ium supplementation on the proportion of participants
with ATD treatment failure, that is, failure to remain eu-
thyroid without further treatment one year after cessation
of ATD treatment.
The secondary objectives are to investigate the effect
on thyroid-specific QoL, level of TSH-receptor antibody
(TRAb), hyperthyroid symptoms, eye symptoms, ad-
verse reactions, and serious adverse events. Further, we
wish to explore the effect of selenium on ATD treat-
ment duration, incidence of Graves' orbitopathy, and
hypothyroid symptoms.
Design
The GRASS (GRAves’ disease Selenium Supplementation
trial) trial is an investigator-initiated, randomised, blinded,
multicentre clinical trial of selenium supplementation ver-
sus placebo in patients with Graves’ hyperthyroidism. The
trial has a parallel-arm design with 1:1 allocation to the
experimental intervention group and the control inter-
vention group, and involving seven clinical trial sites in
Denmark (see Figure 1). The trial also includes a ques-
tionnaire and register-based follow up period up to ten
years after completion of the intervention period.
Trial participants
All patients with current hyperthyroidism, who are re-
ferred to or being followed at the participating clinical trial
sites, are considered for participation. Patients are eligible
for the GRASS trial, if they comply with the following in-
clusion and exclusion criteria.
Inclusion criteria
The inclusion criteria are: Graves’ hyperthyroidism (first-
time diagnosis, defined as patients not yet receiving
ATD treatment, or having received ATD treatment con-
tinuously for less than two months, or relapse of Graves’
hyperthyroidism defined as patients previously having
received and discontinued treatment with ATD); active
Graves' hyperthyroidism (TSH <0.1 mU/L and positive
TRAb according to local laboratory results) measured
within the last two months prior to the inclusion date; age
18 years or older; provision of written informed consent.
Exclusion criteria
The exclusion criteria are: major co-morbidity, rendering
the participants unlikely to continuously receive the trial
intervention; previous treatment with radioactive iodine;
ongoing ATD treatment for more than two months; treat-
ment with immunomodulatory drugs, such as cyclospor-
ine A, methotrexate, cyclophosphamide; allergy to the
components in the selenium and placebo pills; pregnancyor breast-feeding; intake of selenium supplementation
above 70 μg per day; inability to read and understand
Danish; lack of provision of informed consent.
Trial intervention
Selenium
The compound used in this trial is organic selenium, in the
form of selenium yeast, which mainly consists of
selenomethionine. The specific product is Organisk selen,
100 μg tablets and is produced by Jemo-Pharm A/S,
Stege, Denmark (http://www.jemo-pharm.dk/frame.cfm/
cms/id=977/sprog=2/grp=6/menu=1/). The daily dose is
set at 200 μg (two tablets taken in the morning). The trial
dosage is based on the available clinical data, is not consid-
ered to cause adverse reactions, and is lower than the upper
tolerable intake level of 300 μg per day [6,7].
Placebo
Placebo tablets, identical in size, appearance, taste, smell,
and solubility to the experimental intervention tablet are
produced by Jemo-Pharm A/S. They have the same con-
tent as Organisk selen but are without selenium, as the
selenium yeast has been exchanged with yeast grown in
selenium-deplete media. The placebo regimen is identi-
cal to the selenium regimen.
Randomisation
Randomisation will be performed centrally. The allocation
sequence is computer-generated with a varying block
size kept unknown to the investigators. Randomisation
is stratified by clinical trial site and disease status (inci-
dent or relapse), and the allocation ratio is 1:1.
Informed consent procedure
Potential participants are identified at referral or visits
to the outpatient clinics and include all patients with
current hyperthyroidism (that is, elevated thyroid hor-
mone levels). Where Graves’ hyperthyroidism is confirmed
(that is, TRAb is positive), the potential participant is
invited to an information visit by letter. The visit con-
sists of obtaining history, blood sampling, information
about trial contact, and randomisation.
Duration
The intervention period for each participant will be 24
to 30 months, as selenium will be given until 12 months
after cessation of ATD treatment, which usually lasts 12
to 18 months (Figure 2). The total trial duration is expected
to be about 4 years (inclusion period about 17 months
and up to 30 months intervention period).
Concomitant medication or treatment
The trial participants receive conventional ATD treatment.
Treatment of hyperthyroidism, will take place within the
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Figure 1 Trial flow chart.
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standards set by the departments. ATD treatment with-
drawal must be considered or attempted 18 months after
randomisation at the latest.
Participants are advised not to take extra selenium
supplementation during the trial. A dose of <70 μg per
day is allowed (the content in multivitamin tablets is 55 μg).
The participants’ consumption of additional selenium
supplements will be monitored during the trial through
self-report forms.
Monitoring for intervention compliance
Participant compliance with the intervention will be
monitored by self-reported tablet intake at 6 and 12 weeks,
and 6, 12 and 24 months (Table 1), and by tablet-countingat trial visits at 18 months and at the end of the interven-
tion (24 to 30 months). An investigator will contact the
patient if the trial data management system flags a par-
ticipant as non-compliant (or overdosing), according to
self-report of the number of unopened containers.
Discontinuation
A participant who no longer wishes to participate in the
trial can withdraw his/her informed consent at any time
without need of further explanation, and this will not
have any consequences for the participant’s further treat-
ment. In order to conduct intention-to-treat analyses
with as few missing data as possible, the investigator
may ask the participants which aspects of the trial, they
wish to withdraw from. These can include the following:
Randomisation End of antithyroid treatment
(approximately 12-18 months 
after randomisation)
Follow up visit II
12 months after end of 
antithyroid treatment
12 months0 months 18 months 24-30 months
Intervention period 
(total time: 24-30 months)
Follow up visit I
18 months after 
randomisation
Figure 2 Duration of the intervention.
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remaining follow up assessments, and analysis of data
already collected. The investigators will discontinue a
participant’s taking of the trial intervention at any time,
if the participant: experiences intolerable adverse reac-
tions; is diagnosed with any of the exclusion criteria dur-
ing the intervention period; is referred for ablative therapy
(radioactive iodine or thyroid surgery) during the inter-
vention period. In all three cases, the investigator and/orTable 1 Trial schedule for assessments
Variable Inclusion
(baseline)
6
weeks
12
weeks m
Visit x
ATD treatment
Thyroid function x1
TSH-Receptor Antibodies x1
Serum selenium x
Creatinine/iodine ratio in spot urine x
Storage samples (blood and urine) x
ThyPRO xr xr xr
Tablet count xr xr
Consumption of additional selenium
Adverse events* xr xr
Serious adverse events
Referral to ablative therapy
All assessments must be made at the time points specified above. If the assessmen
and the time shall be noted in the electronic case report form (eCRF). Following thi
practice (f = free (non-protein bound)), that is, all measured analyses are collected c
samples after trial completion; xr, self-reported data by participant;
†participants for
unsuccessful, will be followed up at 36 months after randomisation (± 1 month). AT
patient-reported outcome.the treating physician will, if possible, encourage the
participant to continue with follow up assessment and
to allow the use of collected data in the analyses.
Blinding
Blinding will be maintained for all parties in the trial,
throughout all aspects of the trial. The trial interventions
will be identical, and will be packed in identical packages
by the Capital Region Pharmacy, and therefore, knowledgeFollow up
6
onths
12
months
18
months
24
months
12 (± 1) months after ATD
treatment withdrawal†
x x
x x x
x1 x1
xs xs
(xs) (xs)
x x
xr xr xr xr xr
xr xr xr xr xr
xr xr xr xr
xr xr xr xr xr
x
x x
t is not possible at the specified time, the assessment shall still be conducted,
s, deviations from the protocol can be assessed. 1As part of usual clinical
ontinuously from medical systems; xs, analysed on stored plasma/serum
whom ATD treatment withdrawal has not been attempted, or has been
D, anti-thyroid drugs; TSH, thyroid stimulating hormone; ThyPRO, thyroid
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ticipants and investigators. All outcome assessments
will be performed blinded and statistical analyses will be
performed with the blinding intact.
Safety
Selenium is tolerated in short-term doses up to 10,000 μg
(that is, 100 experimental GRASS tablets). Acute intoxi-
cation is very rare and has only been related to accidental
or suicidal intake [4,21,22]. Chronic intoxication requires
long-term intake of at least 800 μg per day [23], according
to epidemiological studies in areas with very high selenium
content in the soil. Thus, no signs of chronic intoxica-
tion have been observed in areas with daily intakes of
up to about 800 μg daily. In geographically highly ex-
posed groups without signs of intoxication the serum
concentrations have been reported to be 148 to 363 μg
per L [24] and 284 to 472 μg per L [23], respectively. In
a study of 200 μg selenium supplementation per day,
the serum concentration reached a plateau at around
190 μg per L [25].
According to the Danish National Food Institute, the
99th percentile for daily selenium intake through diet in
Denmark is 93 μg for men and 72 μg for women. There-
fore, a dosage of 200 μg per day should not bring trial
participants above the established upper tolerable intake
of 300 μg per day. A review of the safety of selenium
supplementation with selenium yeast, which will be used
in the GRASS trial [26], concludes that in about a dozen
supplementation studies, none has shown evidence of
toxicity even up to an intake of 800 μg selenium per day
over a period of years. In conclusion, the experimental
intervention with 200 μg selenium per day is not expected
to cause adverse reactions. Regardless, participants will be
monitored for adverse events.
Overdosing can lead to gastrointestinal discomfort,
hair and nail malformations and loss, peripheral neuro-
logical symptoms, fatigue and dizziness, and, in the case of
very large selenium loads (1,000 times the daily trial dose),
cardiovascular collapse and respiratory distress [21,22].
Assessment and reporting of adverse reactions (ARs):
participants are prompted to self-report ARs at 6 and 12
weeks, and 6, 12 and 24 months, and are questioned
about ARs at the study visits at 18 months of treatment
and 12 months after stopping ATD treatment, respect-
ively. ARs will be reported as a trial outcome. In addition,
participants are instructed to contact their trial contact
person if they experience symptoms suggestive of ARs.
Assessment and reporting of serious ARs (SARs), ser-
ious suspected SARs (SUSARs) and serious adverse events
(SAEs): data on hospital admissions and mortality will be
obtained through national registries at the end of the trial.
Also, participants are informed and instructed to contact
their trial contact person if they are admitted to a hospitalfor selenium intoxication, experience a clinical picture
indicative of selenium intoxication, or experience a clin-
ical picture that is unexpected but suspected to be re-
lated to selenium intoxication. When a possible serious
event (SAE, SAR, or SUSAR) is identified, details will be
sought from the patient’s medical record and through
direct contact with the patient. Any SAE, SAR or SUSAR
will be reported as an outcome measure.
Outcomes
Outcomes will be assessed seven times during the trial
(Table 1).
Primary outcome
The primary outcome is the proportion of participants
with the composite outcome of ATD treatment failure
in participants receiving ATD treatment during the last
12 months (± 1 month) of the intervention period, who
have had thyroid hyperfunction (TSH <0.1) during the
last 12 months (± 1 month) of the intervention period,
or have been referred for ablative therapy (radioactive
iodine or thyroid surgery) at some point during the en-
tire intervention period.
Secondary outcomes
The secondary outcomes are each component of the pri-
mary outcome as follows: proportion of participants who
receive ATD treatment (at any level) during the last 12
months (± 1 month) of the intervention period (separate
component of the primary outcome); proportion of partic-
ipants who have thyroid hyperfunction (TSH <0.1) during
the last 12 months (± 1 month) of the intervention period
(separate component of the primary outcome); proportion
of participants who have been referred to ablative therapy
(radioactive iodine or thyroid surgery) at some point
during the entire intervention period (separate compo-
nent of the primary outcome); thyroid-specific QoL dur-
ing the first year after randomisation, and at the end
of the intervention period (24 to 30 months), as mea-
sured by the global score in the ThyPRO questionnaire
(Appendix 1); level of TRAb at 18 months, and at the
end of the intervention period (24 to 30 months); hyper-
thyroid symptoms (ThyPRO subscale) during the first year
after randomisation; eye symptoms (ThyPRO subscale)
during the first year after randomisation, and at the end
of the intervention period (24 to 30 months); number of
patients with ARs during the intervention period, and
number of patients with serious adverse events during
the intervention period.
Exploratory outcomes
The following outcomes are of an exploratory nature:
time to ATD treatment withdrawal (unsuccessful partici-
pants will be censored at 18 months); cost-effectiveness
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orbitopathy during the intervention period, assessed as
clinical activity score (CAS) >1 among patients with CAS
scoring in the medical chart, and hypothyroid symptoms
(ThyPRO subscale) during the intervention period.
The trial data management system
As a result of the pragmatic design with minimal
participant-trial interaction, a large part of the data col-
lection, trial conduct, and trial surveillance and timing
is handled by the trial data management system. This
trial data management system consists of a patient-
survey-interface, a trial-personnel-interface, a system-
integration interface and a programme motor. The system
will be used for collection of outcomes, adverse events, and
other trial-relevant information; for timing of trial events,
that is, time for patient-reported outcomes and trial visits;
for identification of need for actions (for example, contact
to a participant); and for delivery of output to personnel or
participants (for example, email notifications).
Research biobank
A research biobank for serum/plasma and urine samples
will be established. The samples will initially be kept at
each clinical trial site, and will later be analysed at central
laboratories. Participants are informed verbally and in
writing, and will consent to the withdrawal and storing of
biological material in the GRASS trial. Any remaining
samples will be transferred to a Biobank designated for
future use. These samples will be used for genome-wide
association studies (of predictors for remission and experi-
mental intervention effects, or other indicators of auto-
immunity), as may be specified in forthcoming protocols.
Monitoring
The trial will be monitored according to the International
Committee of Harmonization (ICH) guidelines for good
clinical research practice [27] by internal monitoring.
Statistical analysis
Primary outcome: ATD treatment failure - sample size
estimation
Prior data indicate that the proportion of patients in the
placebo group with ATD treatment failure is 50% [28]. If
the true proportion with ATD treatment failure is 37.5%
among selenium-treated participants (that is, a relative
risk reduction of 25%), we will need to include 492 par-
ticipants (246 experimental and 246 control participants)
to be able to reject the null hypothesis with a power of
80% and a risk of type I error of 5%.
The patient catchment areas of the participating cen-
tres include 1,640,000 persons. Assuming an annual inci-
dence of Graves' hyperthyroidism of 40 per 100,000 after
iodine fortification [1,29] and 50% recurrence rate, theincident population (including recurrences) will be 788
patients annually. Assuming an inclusion of 45% of the
potential patients, this will lead to about 29 participants
per month and an inclusion period of about 17 months.
Secondary outcomes - power estimation
For the ThyPRO Global score, hyperthyroid symptoms
and eye symptoms, if the true difference between experi-
mental and the control participants is 5 (on a scale of
0 to 100) with SD of 20, we will be able to reject the null
hypothesis that the population means of the experimental
and control groups are equal with a probability (power) of
79%. The associated type I-risk is 5%.
For the level of TRAb, if the true difference in TRAb
between experimental and control participants is 0.15 IU
per L with SD of 0.5 IU per L, we will be able to reject
the null hypothesis with a probability (power) of 91%
and a type I error-risk of 5%.
For the number of patients with adverse reactions, prior
data indicate that the proportion of participants who
experience adverse reactions in the control group is
about 5% [26]. If the true proportion of participants in
the experimental group who experience adverse reac-
tions is 10%, we will be able to reject the null hypoth-
esis that the failure rates for experimental and control
participants are equal with probability (power) 50%. The
type I error probability associated with this test is 5%.
Data analysis
All analyses will be intention-to-treat analyses with the
intervention group concealed until two conclusions are
drawn. The significance test will be at the 5% level and
two-sided. Table 2 shows the priority for each outcome,
when it will be measured, the mathematical type of meas-
ure, and the analytical procedure to be used when analyz-
ing the outcome values.
Analytical procedures
Depending on the specific type of outcome measure, one
of five types of regression analysis will be applied (Table 2).
Indicator variable I (1 if X and 0 if Y) is included as a
covariate and the outcome measure (y) as the dependent
variable. All analyses will be conducted both as un-
adjusted analyses and adjusted for stratification variables
(clinical trial site and disease status (incident or relapse)).
Discrepancies between the results of the two analyses will
be discussed. For each covariate, an exploratory analysis,
including the interaction between the covariate and the
intervention indicator, will be conducted.
If the distribution of the primary outcome measure
differs significantly between the two intervention groups,
and the percentage of missing values is larger than 5%,
multiple imputations (MI) will be used. If so, the result
obtained by imputation will be the primary result. In all
Table 2 Outcome measures, their priorities, times of measurement, mathematical types and analytical categories
(defining the statistical analysis to which they will be subjected)
Outcome Times of measurements Type of quantity Regression analysis to be applied
Primary outcome
ATD treatment failure End of trial Binary Logistic regression
Secondary outcomes
1. ATD treatment within last 12
months
End of trial Binary Logistic regression
2. Thyroid hyperfunction after
ATD treatment withdrawal
End of trial Binary Logistic regression
3. Ablative therapy End of trial Binary Logistic regression
4. Global QoL ThyPRO score a) Time sequence of five
measurements†
Numerical a) Mixed-model with repeated measures (MMRM)
b)12 months following ATD
treatment withdrawal‡
b) General linear univariate model. As sensitivity
analysis: Mann-Whitney test
5. Level of TRAb After 18 months and at the
end of intervention period
Numerical General linear univariate model. As sensitivity analysis:
Mann-Whitney test
6. ThyPRO - hyperthyroid
symptoms
a) Time sequence of five
measurements†
Numerical a) Mixed-model with repeated measures (MMRM)
b) 12 months following ATD
treatment withdrawal‡
b) General linear univariate model. As sensitivity
analysis: Mann-Whitney test
7. ThyPRO - eye symptoms a) Time sequence of five
measurements†
Numerical a) Mixed-model with repeated measures (MMRM)
b) 12 months following ATD
treatment withdrawal‡
b) General linear univariate model. As sensitivity
analysis: Mann-Whitney test
8. Adverse reactions End of trial Rate = count/period of
intervention/day
Generalised linear model, Poisson distribution,
link = log. As sensitivity analysis: Mann-Whitney test
9. Serious adverse reactions End of trial Rate = count/period of
intervention/day
Generalised linear model, Poisson distribution,
link = log. As sensitivity analysis: Mann-Whitney test
Exploratory outcomes
1. Time to ATD withdrawal § End of trial Numerical (time until ATD
withdrawal (or censoring))
Cox proportional hazard rate model.As sensitivity
analysis: Kaplan-Meier estimates of survival function
2. Incidence of Graves’
orbitopathy - CAS score
End of trial Binary (CAS >1) Logistic regression
3. ThyPRO - Hypothyroid
symptoms
a) Time sequence of five
measurements†
Numerical a) Mixed-model with repeated measures (MMRM)
b) 12 months following ATD
treatment withdrawal‡
b) General linear univariate model. As sensitivity
analysis: MannWhitney test
†This analysis (2) includes four measurements relative to the reference time (6 weeks, 12 weeks, 6 months and 12 months). ‡This analysis (3) includes one
measurement (12 months following ATD treatment withdrawal or failure to withdraw (alternative treatment instituted or deadline expired)) relative to a different
reference time. §End of ATD treatment or censoring at 18 months after randomisation or ablative surgery, provided the latter takes place during ATD treatment
and prior to time of censoring. ATD, anti-thyroid drugs; QoL, quality of life; ThyPRO, thyroid patient-reported outcome; TRAb, TSH-receptor antibodies; CAS, clinical
activity score.
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ing values will be assessed using a worst- and best-case
scenario. The gate keeping method of Dmitrienko et al.
[30] will be used to adjust the observed P-values.
Ethical considerations
The GRASS trial has been approved by the Regional Ethics
Committee (H-4-2012-026). The trial will be conducted
in compliance with the guidelines of the latest Declar-
ation of Helsinki and the International Conference on
Harmonization (ICH) Good Clinical Practice (GCP)
Guidelines [27].Publication plan
The aim is to publish all results, positive, neutral, and nega-
tive, in peer-reviewed international journals. Authorship
will be determined according to the guidelines from the
International Committee of Medical Journal Editors [31].
Discussion
The design of the GRASS trial has faced three major
challenges: the intent to conduct it as a pragmatic trial
with as little interference with daily clinical management
as possible, while still measuring QoL meticulously; the
intent to comply with the ICH guidelines for GCP, even
Watt et al. Trials 2013, 14:119 Page 9 of 10
http://www.trialsjournal.com/content/14/1/119though the intervention is widely considered to be non-
toxic and rather, a supplemental nutrient than a drug;
and the need for a very long intervention period.
It was of great importance to the initiators of this trial,
that the results would be directly applicable to daily clin-
ical practice. Therefore, it was decided to conduct a
pragmatic trial [32], with as little interference with daily
clinical practice as possible. This could be accomplished
by letting the patients follow their usual treatment at
their usual hospitals by whichever physician was involved
in their treatment. At the same time, we found it import-
ant to collect high quality data on the clinical course and
QoL. We have, therefore, put great effort into the design
of a trial management system, which could solve this
schism of distance from participants compared to close
monitoring. The system initiates and keeps track of patient
input (QoL-measurements and other patient-reported
outcomes), identifies need for trial personnel input and ac-
tion, and collects data on thyroid function from medical
chart systems. The system also identifies the site of the
information-provider, as well as the disease status of new
participants, and delivers randomisation codes stratified
by site and disease status. Meticulous follow up on missing
responses to the QoL measurements is incorporated into
the system, to minimise the usual major problem with
missing QoL data in clinical trials.
Somewhat similarly, the need to monitor adverse reac-
tions and events in accordance with the ICH guidelines
was in conflict with the intent to interfere as little as
possible and with the fact that no previous selenium trial
has identified any adverse reactions, which would also
be quite surprising, given the wide therapeutic range of
this dietary supplement. This is solved by a combination
of thorough instruction of the participants to contact
their trial person in case of symptoms indicative of adverse
reactions or events, surveillance of patient-responses to
prompts through the trial management system, and inte-
gration with national databases regarding hospitalizations.
The third issue was the decision to continue trial
intervention until one year after stopping anti-thyroid
drugs (ATD treatment withdrawal). Patients are not con-
sidered in remission unless they are still euthyroid one
year after stopping medication. Since selenium is consid-
ered to have an attenuating effect on thyroid autoimmun-
ity, a long duration of treatment was considered necessary
to test our hypothesis, that is, that selenium can indeed
lead to more patients staying in remission (and not just
reaching euthyroidism faster and obtaining better QoL).
Trial status
The first patient was enrolled in December 2012.
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